T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments.
Victoria A VardellDaniel A ErmannLindsey FitzgeraldHarsh R ShahBoyu HuDeborah M StephensPublished in: American journal of hematology (2024)
Survival remains poor for T-cell prolymphocytic leukemia, though treatment in recent years, associated with access to novel therapies, and management at academic medical centers is associated with improved outcomes. There remains a critical need to improve the available treatment options for this population, and access to specialized academic medical centers, comprehensive supportive care, clinical trials, and early palliative care remains essential for T-PLL patients.
Keyphrases
- palliative care
- healthcare
- clinical trial
- end stage renal disease
- acute myeloid leukemia
- advanced cancer
- bone marrow
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- risk factors
- type diabetes
- randomized controlled trial
- quality improvement
- adipose tissue
- medical students
- combination therapy
- phase ii
- insulin resistance
- study protocol
- replacement therapy